1. Introduction {#s0005}
===============

Quercetin is a flavonoid, a natural substance with a phenolic structure. Flavonoids can be divided into various classes on the basis of their molecular structure with quercetin belonging to the flavone class, which has a planar structure due to the double bond in the central ring of the 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one) backbone. This flavonoid group can be found in abundance in onions, apples, broccoli, and berries ([@b0005], [@b0010]). Quercetin pharmacokinetics and bioavailability in humans has previously been studied ([@b0015], [@b0020]). An important effect of quercetin is its ability to scavenge for oxygen-derived free radicals ([@b0025]), given its antioxidant properties at low concentrations ([@b0030]). Furthermore, *in vitro and in vivo* experiments have also shown that flavonoids possess potential anti-inflammatory, anti-allergic, antiviral, anti-carcinogenic and anti-asthmatic properties ([@b0035], [@b0040], [@b0045], [@b0050], [@b0055], [@b0060]).

Specifically, for the lungs, cell culture studies have shown that quercetin can reduce infectivity of target cells and replication against a wide variety of respiratory viruses, including herpes simplex virus and adenovirus ([@b0065]), coronavirus ([@b0070]), parainfluenza and respiratory syncytial virus ([@b0075]), rhinovirus ([@b0080]), and severe acute respiratory syndrome ([@b0085]). Furthermore, there is evidence that quercetin plays a critical role in the amelioration of the pathogenic process of asthma in a murine model (mice) ([@b0090]), due to the alteration of specific cytokine production (Th1/Th2) and transcriptor factors (T-bet and GATA-3) gene expression in OVA-induced asthma model mice, suggesting quercetin could be used as a new therapeutic approach to allergic airway diseases. More recently, when given orally to guinea pigs, quercetin has been found to reduce hyper-reactivity of airways, one of the main attributes of allergic asthma ([@b0095]); causing significant broncodilation.

Furthermore, a report suggests that flavonoids such as quercetin and luteolin could stimulate Cl^−^ secretion by activating an entry step of Cl^−^ across the basolateral membrane through Na^+^/K^+^/2Cl^−^ co-transporter; contributing to maintenance and/or production of airway surface liquid by regulating Cl^−^ secretion in airway epithelial cells ([@b0100]), very important in chronic obstructive pulmonary disease.

Quercetin is sparingly soluble in water and has poor bioavailability. As a result, the clinical application of the drug is greatly restricted. Previous studies have tried to resolve this issue by producing nanocrystals with enhanced dissolution ([@b0105], [@b0110]). An alternative approach would be to incorporate the drug into a lipid matrix ([@b0110]). The production of solid lipid microparticles (SLMs) has been previously studied as a respiratory drug delivery vehicle for both poorly water-soluble drugs, such as budesonide ([@b0115]) and for more water-soluble drugs, such as salbutamol ([@b0120]). There are many advantages in using SLMs ([@b0125]), with the most significant being the ability to control release after deposition. Furthermore, SLMs should be well tolerated *in vivo* since they are made of physiological compounds. Of course, the toxicity of the surfactants and other excipients, used for their manufacture, needs to be considered.

While solid lipid nanoparticles are currently attracting a lot of attention in the research community, solid lipid micropatrticles have been rather unexploited, especially for inhalation drug delivery ([@b0115], [@b0120], [@b0125]), where particles should have an optimum aerodynamic diameter between 1 and 6 μm ([@b0130]). [@b0115], [@b0120] used this concept to deliver budesonide and salbutamol, two anti-asthma drugs, respectively, using glycerol behenate as the solid lipid component. In other studies, [@b0135], used dipalmitoylphosphatidylcholine, a biocompatible lipid and component of normal lung surfactant, to modulate immunoglobulin release while [@b0140] applied the same concept for the formulation of SLMs to be used as carrier for lung delivery, using Compritol 888 as lipophilic component and Poloxamer as emulsifying agent.

The aim of this study was to investigate the potential use of solid lipid microparticles containing quercetin delivered as a dry powder for inhalation. The physicochemical characteristics of this formulation was investigated together with aerosol performance, *in vitro* cell toxicity and transport studies, using a Calu-3 adenocarcinoma cell line grown using an air-interface model.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

Micronised quercetin hydrate (referred to as quercetin hereafter) and tristearin were supplied by Sigma Aldrich (Steinheim, Germany). Phosphatidylcholine was supplied by Cargill (Hamburg, Germany). Ammonium acetate was supplied by Ajax Finechem Pty Ltd. (Sydney, Australia). Acetic acid was purchased from AnalaR VWR International (Poole, England) and EDTA di-sodium salt was supplied by APS Finechem (Sydney, Australia).

The Calu-3 cell line (HTB-55) was purchased from the American Type Cell Culture Collection (ATTC, Rockville, USA). Dulbecco's modified Eagle's medium, fetal bovine serum, Hanks balanced salt solution, phosphate buffer saline, HEPES, trypsin--EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), [l]{.smallcaps}-glutamine solution (200 mM), nonessential amino acids solution and CelLytic M Cell Lysis (50 mM Tris--HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) were supplied by Invitrogen (Sydney, Australia). Transwell cell culture supports (0.33 cm^2^ polyester, 0.4 μm pore size) were obtained from Corning Costar (Lowell, MA, USA).

All solvents were analytical grade and were obtained from Sigma (Sydney, Australia).

Water was purified by Milli-Q reverse Osmosis (Molsheim, France).

2.2. Methods {#s0020}
------------

### 2.2.1. Preparation of the solid lipid microparticles {#s0025}

For the development of SLMs loaded with quercetin, melt o/w emulsification technique was employed, since it circumvents the use of organic solvents ([@b0115], [@b0125]). This approach is environmentally friendly, but also eliminates the potential for residual solvent in the final dosage form. Quercetin (1 g) was dissolved into a melted (70--75 °C) lipid phase (3.6 g tristearin) and the phase inversion was obtained adding hot (70--75 °C) MilliQ water (50 mL), containing 0.7 g of phosphatidylcholine as surfactant. The mixture was maintained at 75 °C and was subjected to high-shear mixing (21,500 rpm for 2 min, using a T-25 Ultra-Turrax; IKA-Werk, Staufen, Germany). Additionally, the o/w emulsion was sonicated at a constant duty cycle (22 kHz) for 2 min, using a probe (Microson XL2000 Ultrasonic Cell Disruptor, Misonix, Farmingdale, NY) at a power input of 80 W. The emulsion was quickly cooled to a room temperature, using an ice bath and the formed microparticles recovered by freeze-drying at −50 °C (Hetosicc, Heto Lab Equipment, Saint-Julie, Canada).

The amount of quercetin entrapped in the SLMs was determined by heating (75°C for 2 min) and sonication (10 min) of the microparticles (20--25 mg) in ethanol in sealed glass vials. The obtained sample was diluted to volume (50 mL) with methanol, filtered and assayed by high performance liquid chromatography (HPLC).

### 2.2.2. Physical and chemical characterisation {#s0030}

#### 2.2.2.1. Particle size analysis {#s0035}

The particle size distribution of the SLMs was analysed using laser diffraction (Malvern Mastersizer 2000, Malvern Instruments Ltd., UK). Samples of powder (ca. 10 mg) were dispersed using the Scirocco dry dispersion unit (Malvern, UK) with a feed pressure of 4  Bar and feed rate of 50%. Samples were analysed in triplicate, with an obscuration value between 0.3% and 10% and a reference refractive index of 1.553.

#### 2.2.2.2. Scanning electron microscopy {#s0040}

The morphology of SLMs particles was studied using a field emission scanning electron microscope (Zeiss Ultra plus, Carl Zeiss Pty Ltd., Sydney, Australia). The samples were sputter coated with gold to a thickness of 15 nm, under an argon atmosphere prior to analysis. Samples were dispersed onto carbon sticky tabs and images were taken at random locations.

#### 2.2.2.3. Differential scanning calorimetry {#s0045}

The thermal response of quercetin raw material and SLM powders were studied using differential scanning calorimetry (DSC 823e; Mettler-Toledo, Schwerzenbach, Switzerland).

Samples (3--5 mg) were crimp-sealed in DSC sample pans and exposed to a 10 °C min^−1^ temperature ramp between 40 and 400 °C. Exothermal and endothermic peak temperatures, onset temperature and heat of enthalpy (Δ*H*) for each peak were determined using STARe software V.9.0x (Mettler Toledo, Greifensee, Switzerland).

#### 2.2.2.4. X-ray powder diffraction {#s0050}

The X-ray powder diffraction (XRPD) pattern for the SLMs was analysed using a D5000 X-ray powder diffractometer (Siemens, Munich, Germany). Measurements were conducted at 25 °C, using Cu Kα radiation at 30 mA and 40 kV, with angular increment of 0.04° s^−1^.

#### 2.2.2.5. Dynamic Vapour Sorption {#s0055}

Dynamic Vapour Sorption (DVS) was used to investigate the relative moisture sorption and stability of the quercetin raw material and SLMs, with respect to humidity. Samples (ca. 15 mg) were added to glass sample pans, which were placed in the sample chamber of a DVS (DVS-1, Surface Measurement Systems Ltd., London, UK). Each sample was dried at 0% RH before being exposed to 10% RH increments for two 0--90% RH cycles (25 °C). Equilibrium moisture content at each humidity step was determined by a dm/dt of 0.0005% min^−1^.

### 2.2.3. HPLC method of quercetin quantification {#s0060}

Chemical analysis of quercetin was performed by High-Performance Liquid Chromatography (HPLC) using a Shimadzu Prominence UFLC system equipped with an SPD-20 A UV--Vis detector, LC-20AT solvent delivery unit, SIL-20A HT autosampler (Shimadzu Corporation, Japan) and NovaPak C18 column (5 μm, 150 × 3.9 mm, Waters, Ireland). The HPLC settings were as follow: detection wavelength 370 nm, flow rate 0.4 mL min^−1^, injection volume 100 μL, and retention time of 4.5 min. The mobile phase was a mixture of acetate buffer and acetonitrile (55: 45, v/v) and 1 mM EDTA. Standard linearity was obtained between 0.2 and 20 μg mL^−1^.

### 2.2.4. *In vitro* aerosol studies {#s0065}

The aerosolisation of quercetin SLMs were analysed using an Aerolizer® dry powder inhalation (DPI) device (Novartis, Surrey, UK) and a next generation impactor (NGI) (Copley Scientific, Nottingham, UK) according to the method specified for dry powder inhalers in the pharmacopoeia ([@b0145]). Briefly, prior to testing, all eight NGI collection cups were coated with silicon oil to eliminate particle bounce. 10 mg ± 0.1 mg of quercetin SLMs were weighed and filled in size 3 gelatine capsules (Capsugel, Sydney, Australia) and placed in the Aerolizer®. A mouthpiece adaptor fitted into a United States Pharmacopeia (USP) throat was used to connect the Aerolizer® to the NGI. The particles were aerolised at 60 L min^−1^ for 4 s. The device containing the capsule, throat and the stages were then washed separately with methanol and the samples were analysed using HPLC. The mass balance was calculated as the recovery from the stage deposition, capsule and device. In addition, the fine particle dose (FPD) (drug recovered from stages 3 to filter) (⩽4.46 μm) and the fine particle fraction (FPF) (FPD/Total dose × 100) were calculated.

### 2.2.5. Cell viability assay after exposure to quercetin SLMs {#s0070}

The toxicity of quercetin SLMs was assessed by measuring the viability of Calu-3 cells in a liquid covered culture, following 3 days drug exposure to increasing drug concentrations, as previously described ([@b0150]).

Briefly, 5 × 10^4^  cells were seeded per well in a volume of 100 μL into a 96 well plate. Cells were incubated overnight at 37 °C in 5% CO~2~ atmosphere. After 24 h, 100 μL of increasing concentrations of quercetin SLMs were added to each well, and the drug was dissolved in ethanol and added to complete medium in a final ethanol concentration of ⩽1%. Untreated controls and solvent controls were included for each experiment. Plates were incubated for 72 h at 37 °C in a humidified atmosphere with 5% CO~2~. Cells were then analysed for cell viability. Briefly, 20 μL of CellTiter 96® Aqueous assay (MTS reagent) (Promega, USA) was added to each well and the plates incubated for 3 h at 37 °C in humidified 5% CO~2~ atmosphere. Absorbance was measured at 492 nm using a POLARstar Optima (BMG Labtech, Offenburg, Germany). The absorbance value was directly proportional to cell viability (%). Data were expressed as % cell viability \[(average absorbance of treated wells/average absorbance of control wells) × 100\]. The half maximal inhibitory concentration (IC~50~) values were defined as the drug concentration that produces a decrease of 50% in cell viability compared to the untreated control. IC~50~ values were calculated by plotting (%) cell viability against the concentrations (ng mL^−1^) on a logarithmic scale. Data was fitted to the Hill equation using the General Fit function of KaleidaGraph 4.1 software. Each experiment was performed in triplicate.

In addition, measurement of the transepithelial electrical resistance (TEER) was performed using EVOM voltohmmeter (World Precision Instrument, USA) connected to STX-2 chopstick electrodes. 10 measurements were taken per well after the experiment to confirm the maintenance of barrier integrity over 4 h of experiment. Subtracting the resistance of a cell-free insert and correcting the value for the surface area of the Transwell calculated the resistance.

### 2.2.6. *In vitro* drug diffusion/transport studies using air interface Calu-3 cell culture {#s0075}

The transport of quercetin from the SLMs was studied using a Calu-3 lung epithelial model. The culture conditions for the Calu-3 cell air interface model were as previously described ([@b0150]). Briefly, Calu-3 cells were grown and subcultured in Dulbecco's Modified Eagle's medium (F-12 containing 10% (v/v) fetal calf serum, 1% (v/v) non essential amino acid solution and 1% (v/v) [L]{.smallcaps}-glutamine solution). Cells were then seeded on Transwell polyester inserts at a density of 5 × 10^5^  cells cm^−2^. After 24 h, medium was removed from the apical chamber and the basolateral medium replaced every alternate day with fresh medium to establish an air-interface model over 12--14 days. Prior to transport studies the viability and integrity of the cell monolayer with respect to quercetin SLMs was evaluated.

A modified *in vitro* aerosol testing apparatus (twin stage impinger TSI, Radleys, Essex, UK) that allows the attachment of a Transwell containing Calu-3 epithelial cells was used to study the mechanism of drug deposition, dissolution and diffusion/transport ([@b0150], [@b0155]). Before the drug transport studies, the TSI flow rate was set to 60 L min^−1^ using a rotary vein pump and a calibrated flow meter. The quercetin SLM sample was weighed (1 mg ± 0.05 mg) into a size 3 gelatine capsules, which was then insert into an Aerolizer® device and the pump activated for 4 s to disperse the powder. The TSI was then disassembled and the Transwell removed. After deposition of the powder, the Transwell was placed into a 24 well plate containing 300 μL modified buffer (HBSS supplemented with HEPES (1% v/v), and ethanol 97% (1% v/v) at pH 7.4) to measure the quercetin transport.

At 30 min time points the Transwells were moved to new well containing fresh modified buffer. After 4 h the surface of the monolayer was washed with transport buffer to account for the drug remaining on cell surface and the cells were lysed with Cell Lytic solution to allow the measurement of the drug in the cells. The lysates were centrifuged at 10,000 rpm for 10 min at 4 °C. The supernatant was collected and diluted to an appropriate volume. All the samples were analysed by HPLC. The initial amount deposited on the cell layer was calculated from the sum of the drug passed through the cell monolayer, the mass retained on the monolayer at the end of the experiment and the mass of drug inside the cells. Experiments were randomised for dose and repeated three times.

### 2.2.7. Statistical analysis {#s0080}

Data was subjected to statistical analysis (SPSS 17.0), using ANOVA one-way analysis to examine for significant difference. Significant differences between formulations were analysed using multiple comparisons (Tukeys post hoc test) and *P* values of \<0.05 were considered to be significant.

3. Results {#s0085}
==========

3.1. Physicochemical characteristics of quercetin solid lipid microparticles {#s0090}
----------------------------------------------------------------------------

For the preparation of the SLMs, tristearin and hydrogenated phosphatidylcholine were selected respectively as lipidic material and surfactant, based on a previous study on the development of quercetin-loaded lipid microparticles for dermal application ([@b0160]). In addition, phosphatidylcholine is a physiological compatible emulsifier (phosphatidylcholine is the major component of lung endogenous surfactant). The quercetin content of the SLMs was 15.5% w/v ± 0.6, which corresponded to an encapsulation efficiency of 71.4% (encapsulation efficiency is based on the recovered amount of quercetin in the microparticles as a function of the theoretical amount present in the powder when taking into account the excipients content) .

### 3.1.1. Particle size analysis {#s0095}

The particle size distribution of the as supplied micronised quercetin and quercetin SLMs are shown in [Fig. 1](#f0005){ref-type="fig"} with analysis of the data indicating median volume diameters (*d* ~0.5~) of 2.28 ± 0.03 μm and 2.90 ± 0.30 μm, respectively. Further analysis suggested 90% of the SLMs had a diameter ⩽11.08 ± 1.09 μm.Fig. 1Particle size distribution of raw quercetin and quercetin SLM measured using dry dispersion system of laser diffraction. Data represent mean ± SD (*n* = 3).

### 3.1.2. Scanning electron microscopy {#s0100}

Scanning electron microscopy images of the SLMs and as-supplied quercetin are shown in [Fig. 2](#f0010){ref-type="fig"} A and B, respectively. In general the SLMs particles had a spherical morphology and a size in line with particle size analysis, while raw quercetin was columnar in shape and larger than 10 μm. It is important to note that particle size data is represented as volume distribution and makes a series of assumptions (i.e. uniform spheres), while SEM is a 'morphological' technique. This is reflected by the differences observed in particle size when compared with SEM images, where particles appear to have an elongated or plate-like morphology. Particle size distribution for the SLMs was of an appropriate size for respiratory delivery ([@b0130]) and similar to that measured using laser diffraction.Fig. 2Scanning electron micrographs of quercetin SLMs (A) and raw quercetin (B).

### 3.1.3. Differential scanning calorimetry {#s0105}

The thermal response of the SLM components; tristearin, phosphatidylcholine and quercetin, as well as the prepared SLMs are displayed in [Fig. 3](#f0015){ref-type="fig"} . Tristearin is a commercial monoacid triglyceride. Generally, triglycerides exhibit three different polymorphic forms characterised by particular chain packing and thermal stability: alpha (α), beta-prime (β′), and beta (β) ([@b0165]). In this specific experiment, tristearin presented an endotherm corresponding to the melting of the β phase at 63.75 °C, similar to previous literature ([@b0170]). Phosphatidylcholine is a surface-active molecule. Its transition temperature from crystalline to mesomorphic (liquid crystalline) was visible at around 84.22 °C, in agreement with previously reported values ([@b0175]).Fig. 3Differential scanning calorimetric thermograms of quercetin SLM, quercetin raw material, phosphatidylcholine and tristearin.

The DSC thermogram of quercetin raw material exhibited an endothermic peak at 321 °C, typical of melting, in line with literature data ([@b0180]). Another smaller endothermic peak is visible at around 137 °C related to a decomposition process with water loss ([@b0185]).

The DSC thermogram of the prepared SLMs showed a noticeable reduction in the melting point in comparison with quercetin raw material, followed by an endothermic response. These results are supported by various previous studies conducted on the phospholipid complexes of some phytoconstituents such as silybin, puerarin curcumin, naringenin and gallic acid ([@b0190], [@b0195]). It is hypothesised that the main exothermic event is due to the melting of the primary excipient, tristearin and the simultaneous dissolution of the drug and phospholipid in the melt. The significance of the DSC data is that the quercetin appears incorporated into the matrix; an essential requirement with respect to stability and release profile modification.

### 3.1.4. X-ray powder diffraction {#s0110}

The diffractogram of raw quercetin and quercetin SLMs measured using XRPD is shown in [Fig. 4](#f0020){ref-type="fig"} . The XRPD pattern of the starting material indicated a highly crystalline structure, as evident from the sharp peaks observed at 14, 16, and 27 of 2*θ* values. This was in good agreement with a previous study of quercetin ([@b0200]). In comparison, the SLMs had no characteristic peaks of a crystalline structure suggesting the particles to be amorphous. The incorporation of the drug into the lipid matrix is likely to enhance stability of the drug and control release after deposition. This is reflected in the DVS and *in vitro* experiments presented in Sections [3.1.5](#s0115){ref-type="sec"}, [3.4](#s0150){ref-type="sec"}, respectievely.Fig. 4The X-ray powder diffractogram of raw quercetin and quercetin SLMs.

### 3.1.5. Dynamic Vapour Sorption {#s0115}

Dry powder inhalers are inherently susceptible to moisture sorption and thus elevated relative humidity (RH). To further study the SLMs, the powders were exposed to two 0--90% RH cycles using a DVS. Time vs. mass plots as a function of humidity are shown in [Fig. 5](#f0025){ref-type="fig"} A while the moisture sorption isotherm for the first humidity ramp (cycle 1) is shown in [Fig. 5](#f0025){ref-type="fig"}B. In general, all of the formulation components were reversible in terms of moisture sorption/desorption suggesting no irreversible polymorphic change or crystalisation phenomena. The moisture sorption was highest for phosphatidylcholine (14.5% at 90% RH) compared with 0.8% and 0.1% for quercetin and tristearin, respectively. The moisture sorption of the SLMs was 3.3% at 90% RH. The reduction in moisture sorption for the SLMs in comparison to the phosphatidylcholine (which equates for ∼13% of the SLM particle mass) is most likely due to the contributing effects of the drug and tristearin (which make up the majority of the particle) and the presence of phosphatidylcholine on the surface of the particles (contributing to the high humidity sorption of SLMs).Fig. 5Mass change as a function of time for quercetin SLM, quercetin, phosphatidylcholine and tristearin (A) DVS isotherm of the first cycle sorption for quercetin SLM, quercetin, phosphatidylcholine and tristearin (B). Zoomed in area in front view.

3.2. *In vitro* aerosolisation studies {#s0120}
--------------------------------------

The aerosolisation performance of quercetin SLMs was studied using the NGI and the data is presented in [Fig. 6](#f0030){ref-type="fig"} . Analysis of the stage deposition data, capsule and device recovery indicated that 96.87% ± 1.51% of the loaded dose was recovered across all stages (indicating good mass balance). In addition, the fine particle dose (FPD) and fine particle fraction (FPF) were calculated to be 316.2 ± 52.3 μg and 20.5 ± 3.3%. The FPD and FPF represented the dose and percentage drug concentrations with an aerodynamic diameter less than 4.46 μm, suitable for inhalation delivery.Fig. 6Quercetin SLMs aerosol deposition by next generation impaction. S1--S8 represents NGI stages cut off diameters: S1 \> 8.06; S2 \> 4.46; S3  \> 2.82; S4 \> 1.66; S5 \> 0.94; S6 \> 0.55; S7  \> 0.34; S8 \> 0.34 μm, respectively.

3.3. Cell viability assay {#s0125}
-------------------------

The dose response cytotoxicity profile of quercetin SLMs on Calu-3 cells was established and is shown in [Fig. 7](#f0035){ref-type="fig"} . Calu-3 cell cultures were exposed to a range of SLMs concentrations (from a minimum of 0.15 nM to a maximum of 200,000 nM) over a 72 h treatment period. Cells viability was calculated with reference to the untreated cells, where average absorbance was normalised to 100% viability. The viability assay demonstrated that Calu-3 cells could tolerate a wide range of quercetin concentrations. The IC50 value could not be determined across the concentration range and thus, the SLMs should be considered non-toxic for Calu-3 cells.Fig. 7The effect of quercetin SLMs on Calu-3 cell viability after 72 h drug treatment. Data represent mean ± SD (*n* = 3).

TEER of the Calu-3 monolayer was measured after 240 min of exposure to quercetin, quercetin SLMs, tristearin and phosphatidylcholine. This was performed to determine if any of the components in the formulation could change the integrity of the epithelial cells. It was found that there was no significant difference (*P*  \> 0.05) between the control cells and cells treated with quercetin (550 ± 40 Ω cm^2^), quercetin SLMs (550 ± 30 Ω cm^2^), tristearin (580 ± 30 Ω cm^2^), phosphatidylcholine (600 ± 55 Ω cm^2^) or co-deposition of tristearin and phosphatidylcholine (560 ± 23 Ω cm^2^).

Although to the authors' knowledge, no previous viability studies have used Calu-3 epithelial cells, flavonoids are ubiquitous in the human diet, are highly bioavailable, and have been extensively studied with regard to their pharmacology and toxicology ([@b0205]).

Furthermore, multiple laboratory clinical trials point to an excellent safety profile of quercetin, including studies using systemic, oral, and intravenous administration ([@b0210]). Consequently in this study it could safely be assumed that quercetin SLMs are not toxic for the concentrations studied.

3.4. *In vitro* drug diffusion/transport studies using an air interface Calu-3 cell culture {#s0150}
-------------------------------------------------------------------------------------------

The percentage of drug transported through the Calu-3 cell grown on the Transwell in the AIC configuration and attached to the modified TSI apparatus is shown in [Fig. 8](#f0040){ref-type="fig"} . Drug concentrations were measured and expressed in terms of percent total recovery throughout the experiments and data was plotted as mean cumulative percentage (±standard deviation) of drug transport over 4 h. Data analysis demonstrates a linear kinetic profile, with a maximum of 22.32 ± 1.51% drug transported after 4 h from SLM formulation. Importantly, quercetin was not detectable in the basal chamber 4 h after deposition of the micronised quercetin micro particles. Such observations suggest that the rate-limiting step in uptake of quercetin SLMs was linked to the solubility, presumably due to the amorphous nature of quercetin trapped within the solid lipid matrix, since the flux is independent of quercetin concentration remaining on the cell monolayer.Fig. 8Release profiles of quercetin SLMs using a modified TSI air-interface Calu-3 cell model. Data represent mean ± SD (*n* = 3).

After deposition of SLMs on the Calu-3 cells grown in the AIC model, the concentration of quercetin transported into the basal compartment at set time points was measured and the cumulative mass and percentage transport calculated. [Fig. 9](#f0045){ref-type="fig"} depicts the percentage of drug transported, remaining on the cells and trapped within the cells, from the single quercetin and quercetin SLMs.Fig. 9Percentage of total drug remaining on the cell surface, inside the cells or transported to the basal chamber after 4 hours. Data represent mean ± SD (*n* = 3).

After 240 min 45.26 ± 7.23% of quercetin SLMs and \>86.79 ± 1.96% of quercetin alone was still found to be on the cells surface, while 31.25 ± 7.40% and 13.20 ± 1.96% (from SLM formulation and quercetin alone, respectively) was found 'trapped' inside the cells. Only 22.32 ± 1.51% of drug from the SLM formulation was transported across the Calu-3 and was found in the basal compartment. No quercetin raw material was transported to the basal compartment.

4. Discussion {#s0135}
=============

Phosphatidylcholine has previously been shown to have skin penetration enhancing characteristics in other studies ([@b0215]). Specifically, a previous study has also shown that didecanoyl-[l]{.smallcaps}-alpha-phosphatidylcholine enhances the nasal absorption of insulin, in an *in vitro* rabbit nasal mucosa model, by facilitating a paracellular passage through a reversible opening of tight junctions ([@b0220]). Here we studied the deposition and transport of both quercetin SLM and micronised quercetin, alone. The quantities deposited were different between the SLM (0.4 μg) and micronised material (2.8 μg) since we attempted to achieve equivalent deposited masses of powder at the epithelia (i.e. including the lipid components). In addition, the higher mass of micronised sample was additionally tested to study if micronised material would be transported at all.

Only quercetin from SLM produced any epithelial transport across the cell line (although some internalization of quercetin was observed for the micronized samples). The enhancement effect achieved by the lipid microparticles could be traced to a more effective delivery of quercetin to the cells due to increased contact surface between the encapsulated substance and the cells. In addition, since the lipid microparticles enable slow release of quercetin at the cell surface over time, the extent of decomposition/oxidative degradation is reduced compared to the free drug, which is immediately available.

Lipid carrier with incorporated drugs has been demonstrated to increase the absorption and circulation in the body versus stand-alone compounds ([@b0225]). For nontoxic enhancers that have proven successful in *in vivo* studies, additional mechanisms to paracellular enhancement have been suggested ([@b0230]). For instance, increased cell membrane permeability caused by enhancer incorporation into the luminal cell membrane has been suggested ([@b0235]), but how this could induce drug transcellular absorption is unclear.

Although this study indicates that the absorption of quercetin is enhanced by the presence of phosphatidylcholine or tristearin, the real mechanism is still unclear. It is possible that the phospholipid may be incorporated into the luminal cell membrane, and this may constitute the primary step in the mechanism by which phosphatidylcholine affects tight junction permeability. Furthermore, changes in the lipid environment of the cell membrane may affect the basic transport properties of the Calu-3 epithelium. Additional studies are needed to evaluate this possibility.

5. Conclusions {#s0140}
==============

This study has investigated the formulation and aerosol delivery to the lung of solid lipid quercetin microparticles as a potential active pharmaceutical ingredient for asthma therapy. We have demonstrated SLM particle technology can be used to deliver this naturally derived flavonoid for the treatment of range of respiratory diseases. The effect of the absorption enhancing non-toxic excipients in increasing the permeability of quercetin has also been highlighted; making this approach significant, since the raw micronised quercetin was not transported across epithelia. To the authors knowledge no previous studies have investigated quercetin transport mechanism using Calu-3 cell epithelial monolayer. This is an important aspect of the study since the lung epithelia will be the first barrier after deposition in the airways. Further studies are necessary to elucidate the exact mechanism.

Due to the natural physiological composition of the quercetin and its components in the final SLMs, this system has the potential to be used as a 'bio-compatible' delivery system to modulate the release of inhaled dry powder formulations.
